TY - JOUR
T1 - Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma
T2 - The case for aggressive management
AU - Van Besien, Koen W.
AU - Khouri, Issa F.
AU - Giralt, Sergio A.
AU - McCarthy, Philip
AU - Mehra, Rakesh
AU - Andersson, Borje S.
AU - Przepiorka, Donna
AU - Gajewski, James L.
AU - Bellare, Nagendranath
AU - Nath, Rajneesh
AU - Romaguera, Jorge E.
AU - McLaughlin, Peter
AU - Korbling, Martin
AU - Deisseroth, Albert B.
AU - Cabanillas, Fernando F.
AU - Champlin, Richard E.
PY - 1995/5
Y1 - 1995/5
N2 - Purpose: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. Patients and Methods: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. Results: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% ± 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. Conclusion: These results compare favorably with those for autologous BMT, Allogeneic BMT offers considerable promise for the treatment of patients with poorprognosis low-grade lymphoma. Its role should be further defined in prospective studies.
AB - Purpose: To evaluate the role of allogeneic bone marrow transplantation (BMT) in recurrent low-grade lymphoma. Patients and Methods: Between 1989 and 1994, 10 patients with chemotherapy-refractory and recurrent low-grade lymphoma were treated with myeloablative therapy and allogeneic BMT. All patients had poor prognostic features and had been extensively pretreated. Results: Eight patients achieved a complete remission and none have relapsed at a median follow-up time of 816 days (range, 346 to 1,865). Two patients died of early complications. The actuarial survival and failure-free survival rates are both 80% ± 12.6%. For surviving patients, the duration of the current remission exceeds that of any previous remission achieved. Conclusion: These results compare favorably with those for autologous BMT, Allogeneic BMT offers considerable promise for the treatment of patients with poorprognosis low-grade lymphoma. Its role should be further defined in prospective studies.
UR - http://www.scopus.com/inward/record.url?scp=0029004847&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029004847&partnerID=8YFLogxK
U2 - 10.1200/JCO.1995.13.5.1096
DO - 10.1200/JCO.1995.13.5.1096
M3 - Article
C2 - 7738615
AN - SCOPUS:0029004847
SN - 0732-183X
VL - 13
SP - 1096
EP - 1102
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 5
ER -